- Trials with a EudraCT protocol (40)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
40 result(s) found for: Tumor mutational burden.
Displaying page 1 of 2.
EudraCT Number: 2016-002898-35 | Sponsor Protocol Number: CA209-848 | Start Date*: 2018-12-21 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden... | |||||||||||||
Medical condition: Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) DK (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Completed) PL (Completed) BE (Completed) Outside EU/EEA IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002743-26 | Sponsor Protocol Number: 2019PA01 | Start Date*: 2020-02-04 |
Sponsor Name:Paulien van Deutekom Foundation | ||
Full Title: Pembrolizumab alone versus pembrolizumab-chemotherapy in first line NSCLC | ||
Medical condition: non small cell lung cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003857-27 | Sponsor Protocol Number: LUPSA | Start Date*: 2020-01-23 |
Sponsor Name:Radboudumc | ||
Full Title: 177Lu-PSMA Radioligand Therapy for advanced salivary gland cancer, a phase II pilot study. | ||
Medical condition: Salivary gland cancer. More specifically two subtypes: adenoid cystic carcinoma and salivary duct carcinoma. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003708-33 | Sponsor Protocol Number: ML43332 | Start Date*: 2023-03-15 | |||||||||||
Sponsor Name:Roche Farma S.A.U. | |||||||||||||
Full Title: A PHASE II, OPEN LABEL, RANDOMIZED, NON-COMPARATIVE COHORTS STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RISK OF RE... | |||||||||||||
Medical condition: Solid tumors | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-005327-20 | Sponsor Protocol Number: TEMPLE02 | Start Date*: 2022-02-08 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: TEMPLE - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy | |||||||||||||
Medical condition: Metastatic or advanced solid tumors with an intermediate tumor mutational burden | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004176-62 | Sponsor Protocol Number: CLEE011AIT01 | Start Date*: 2018-01-10 | |||||||||||
Sponsor Name:NOVARTIS FARMA S.P.A. | |||||||||||||
Full Title: A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatmen... | |||||||||||||
Medical condition: Hormone receptor-positive (HR+) HER2-negative advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002359-39 | Sponsor Protocol Number: 213406 | Start Date*: 2020-09-18 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||||||||||||||||||
Full Title: A PHASE 1, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF NIRAPARIB AND DOSTARLIMAB IN PAEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMOURS | ||||||||||||||||||
Medical condition: Recurrent or refractory solid tumour | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002814-38 | Sponsor Protocol Number: 69HCL18-0857 | Start Date*: 2019-12-09 | |||||||||||
Sponsor Name:Hospices Civils de Lyon | |||||||||||||
Full Title: TROPHAMET, a phase I/II trial of Avelumab and METhotrexate in low-risk gestational TROPHoblastic neoplasias as first line treatment | |||||||||||||
Medical condition: Low-risk gestational trophoblastic neoplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002537-11 | Sponsor Protocol Number: DART | Start Date*: 2020-01-20 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Durvalumab (MEDI4736) After chemoRadioTherapy (DART) for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients | |||||||||||||
Medical condition: Non-small cell lung cancer (NLCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) LT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003645-41 | Sponsor Protocol Number: STARDUST | Start Date*: 2019-09-13 | ||||||||||||||||
Sponsor Name:FONDAZIONE RICERCA TRASLAZIONALE | ||||||||||||||||||
Full Title: Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroids | ||||||||||||||||||
Medical condition: Non- Small-Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001270-34 | Sponsor Protocol Number: RIMAL1 | Start Date*: 2021-04-19 | |||||||||||
Sponsor Name:Radboud University Medical Centre | |||||||||||||
Full Title: Enhancement of immune response by combining immune checkpoint blockade and radiation in patients with recurrent / refractory malignant lymphoma (re-directing the immune system). | |||||||||||||
Medical condition: patients with recurrent / refractory 9p24.1 amplified malignant lymphomas patients with recurrent / refractory malignant lymphoma without 9p24.1 amplification | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003787-24 | Sponsor Protocol Number: PM-CARE-PNRR-MAD-2022-12375905 | Start Date*: 2023-04-20 | ||||||||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | ||||||||||||||||||
Full Title: Precision Medicine in patients with unresectable CholAngiocarcinoma; RadioEmbolization and combined biological therapy (Single arm, multicenter phase II study investigating the efficacy and safety... | ||||||||||||||||||
Medical condition: Unresectable intrahepatic cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003151-34 | Sponsor Protocol Number: ET17-093 | Start Date*: 2019-01-15 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: A multicenter, randomised, open-label Phase II study to evaluate the clinical benefit of a post-operative treatment associating radiotherapy + Nivolumab + Ipilimumab versus radiotherapy + Capecitab... | |||||||||||||
Medical condition: Triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003755-41 | Sponsor Protocol Number: ERIS | Start Date*: 2021-10-12 |
Sponsor Name:Region Skåne | ||
Full Title: ERIS- EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study | ||
Medical condition: EGFR-mutated non-small cell lung cancer (NSCLC) not amenable for curative treatment intention and candidates for EGFR-inhibitor in first line. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000601-27 | Sponsor Protocol Number: MERCURY | Start Date*: 2022-09-27 | |||||||||||
Sponsor Name:Fondazione GONO | |||||||||||||
Full Title: Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial | |||||||||||||
Medical condition: The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001509-33 | Sponsor Protocol Number: B9991025 | Start Date*: 2018-05-31 | ||||||||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
Full Title: A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH ... | ||||||||||||||||||
Medical condition: Locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), hormone receptor-positive (HR+) / human epide... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) HU (Completed) DK (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004158-17 | Sponsor Protocol Number: GELTAMO-IMCL-2015 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:GELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea) | |||||||||||||
Full Title: Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma. | |||||||||||||
Medical condition: Mantle Cell Lyphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002211-10 | Sponsor Protocol Number: GRASPA-TNBC-2018-02 | Start Date*: 2019-03-20 | |||||||||||
Sponsor Name:ERYTECH Pharma | |||||||||||||
Full Title: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone for the Treatment of Patients with Metastatic or Locally Recurrent T... | |||||||||||||
Medical condition: Triple-Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000366-11 | Sponsor Protocol Number: ENGOT-Ov41/GEICO69-O/ANITA | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO) | |||||||||||||
Full Title: A phase III randomized, double-blinded trial of platinum-based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ov... | |||||||||||||
Medical condition: Recurrent ovarian, tubal or peritoneal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Restarted) FR (Completed) DE (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001546-18 | Sponsor Protocol Number: GETNE-T1913 | Start Date*: 2019-08-19 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Grupo Español de Tumores Neuroendocrinos y Endocrinos (GETNE) | |||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (N... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or of unknown (UK) origin. | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
